BLT
Benitec Biopharma
- Short interest
- 0.01%
- 0.00 pp 30d
- as of 8 Jan 2020
- Reported shorts
- 45.6K
- Shares on issue
- 321.287M
Benitec Biopharma (BLT) company profile
Profile, insiders and operations
Company
AI-generated research profile of Benitec Biopharma
Biotechnology
Gene Therapy
RNA Interference
Clinical Stage
Oculopharyngeal Muscular Dystrophy
Benitec Biopharma Inc. is a clinical-stage biotechnology company headquartered in Hayward, California, focused on developing novel genetic medicines. Its proprietary DNA-directed RNA interference (ddRNAi) platform combines RNA interference with gene therapy to achieve sustained silencing of disease-causing genes with a single administration. The company is advancing ddRNAi-based therapeutics for chronic and life-threatening conditions, including Oculopharyngeal Muscular Dystrophy (OPMD).
Director trades
No director trades found
BLT intelligence dossier
Public-source evidence for this company, with industry drill-up links.
- Tax paid and taxable income records
- Government contracts and public money
- Emissions and trade exposure
- Political donations and lobbying links
Sign in to unlock the dossierFree account · no card required